MET alterations in NSCLC—current perspectives and future challenges
J Remon, LEL Hendriks, G Mountzios… - Journal of Thoracic …, 2023 - Elsevier
Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …
[HTML][HTML] My battle with cancer. Part 1
MV Blagosklonny - Oncoscience, 2024 - ncbi.nlm.nih.gov
In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I
must accomplish a mission. If everything happens for a reason, my cancer, in particular, I …
must accomplish a mission. If everything happens for a reason, my cancer, in particular, I …
MET in non-small-cell lung cancer (NSCLC): cross 'a long and winding road'looking for a target
G Spitaleri, P Trillo Aliaga, I Attili, E Del Signore… - Cancers, 2023 - mdpi.com
Simple Summary Around 3% of patients with Non-Small-Cell Lung Cancer (NSCLC)
harbour a MET exon 14 skipping mutation (METex14). Early mutation identification is …
harbour a MET exon 14 skipping mutation (METex14). Early mutation identification is …
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
R Hsu, DJ Benjamin, M Nagasaka - Cancers, 2023 - mdpi.com
Simple Summary In this narrative review, we discuss the development of capmatinib, a
reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell …
reversible MET tyrosine kinase inhibitor that received approval for advanced non-small cell …
Targeting MET in Non-Small Cell Lung Cancer: An Ever-Expanding Territory
Y Han, Y Yu, D Miao, M Zhou, J Zhao, Z Shao… - JTO Clinical and …, 2024 - Elsevier
MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung
cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive …
cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive …
[HTML][HTML] From osimertinib to preemptive combinations
MV Blagosklonny - Oncotarget, 2024 - ncbi.nlm.nih.gov
Here, I suggest that while first-line osimertinib extends median progression-free survival
(PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual …
(PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual …
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
B Jóri, C Vössing, J Pirngruber, EM Willing, K Arndt… - Current …, 2023 - mdpi.com
EGFR-mutant lung cancers develop a wide range of potential resistance alterations under
therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET …
therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET …
[PDF][PDF] EGFR-TKI 耐药MET 扩增肺腺癌靶向治疗1 例
莫嘉欣， 曹玉婷， 梁嘉琦， 蒋梅 - 大连医科大学学报, 2024 - journal.dmu.edu.cn
患者, 男, 63 岁, 吸烟指数400.2018 年12 月28 日因“体检发现CEA 升高” 于广州市第一人民医院
就诊. 结合影像学检查, 穿刺活检病理, 免疫组化(图1A~ C) 确诊为: 右肺下叶肺腺癌, 伴肝 …
就诊. 结合影像学检查, 穿刺活检病理, 免疫组化(图1A~ C) 确诊为: 右肺下叶肺腺癌, 伴肝 …
Conserved regulatory motifs and resistance mechanisms of the MET receptor tyrosine kinase
G Estevam - 2023 - search.proquest.com
MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways
involved in development and wound repair. MET activation relies on ligand binding to the …
involved in development and wound repair. MET activation relies on ligand binding to the …
Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer
M Al Jaberi, W Clough, S Dalia - Oncotarget, 2023 - ncbi.nlm.nih.gov
Several alterations in the MET gene were identified as targetable oncogenic changes
leading to non-small cell lung cancer (NSCLC). These include genomic amplifications, exon …
leading to non-small cell lung cancer (NSCLC). These include genomic amplifications, exon …